Appendices 274 OTHER PUBLICATIONS Publications 1. Polak TB, Bunnik EM. Financial considerations in expanded access policy for gene therapies: a tough nut to crack. Mol Ther. 2021 Jun 2;29(6):1936. 2. Polak TB, Van Rosmalen J, Dirven S, Herzig JK, Cloos J, Meshinchi S, Döhner K, Janssen JJWM, Cucchi DGJ. Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2022 Oct 1;107(10):2506-2510. 3. Polak TB, Janssen JJWM, Cucchi DGJ. Reply to the Comment on Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2023 Mar 1;108(3):928. 4. Duetz C, Cucchi DGJ, Polak TB, Janssen JJWM, Ossenkoppele GJ, Estey EH, van de Loosdrecht AA. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. Br J Haematol. 2022 Jan;196(2):329-335. 5. Den Hamer DM, Schoor P, Polak TB, and Kapitan D. Improving Patient Pre-screening for Clinical Trials: Assisting Physicians with Large Language Models. arXiv. 2023 Apr. 2304.07396 6. Vermeulen SF, Polak TB, Bunnik EM. Expanded access to investigational drugs in psychiatry: A systematic review. Submitted. Posters 1. Polak TB, van Rosmalen J, Uyl-de Groot CA. Data from Expanded Access Programs: Treatment First, Collection Second? An Overview of FDA and EMA Regulatory Approvals. (ISPOR, 2019) 2. Cucchi DGJ, Polak TB, Ossenkoppele GJ, Rowe JM, Estey EH. Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications,but Less Than 50% of “Positive”Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 – 2015 (ASH, 2021)
RkJQdWJsaXNoZXIy MTk4NDMw